

****Published February 2015****

MarketVIEW: Cholesterol (PCSK9) vaccines (CAT: VAMV045)

Product Name	:	MarketVIEW: Cholesterol (PCSK9) vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + 1 forecast model (.xls)
Therapeutic Area	:	Novel vaccines
Publication date	:	February 2015
Catalogue No	:	VAMV045

Background

Cardiovascular disease(s) (CVD) are prominent within the 10 leading causes of death in high-income countries. The most common manifestations of CVD are coronary heart disease (CHD), ischaemic stroke, and peripheral arterial disease (PAD). Raised low-density lipoprotein cholesterol (LDL-C), smoking, and uncontrolled hypertension are major risk factors the development of CVD. By 2030 almost 24.3M people/year globally are predicted to die from CVD.

Currently Statins (HMG-CoA reductase inhibitors) are the most effective drug class for reducing LDL-C but differ in their LDL-C lowering capacity. In addition, several novel therapies are in development to reduce LDL-C levels in patients with severe hypercholesterolemia. These include PCSK9 inhibitors (monoclonals) of which **Sanofi's SAR236553 (REGN727) PRALUENT™** and **Amgen's evolocumab RAPATHA™** have now been filed for registration in both the US and EU. Both monoclonals were shown to reduce LDL-C levels by 40 to 60% in combination with statins/ezetimibe in high-risk patients and those with homozygous familial hypercholesterolaemia. CVD outcomes studies are now ongoing.

Some companies (Pfizer and AFFiRiS AG) are also investigating the possibility of preclinical PCSK9 vaccines that could help reduce LDL-C levels in high-risk patients who cannot achieve guideline LDL-C treatment goals. Vaccines could have the added benefit of lower cost and less frequency of administration.

This **MarketVIEW** product contains a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of PCSK9 (cholesterol) vaccines + monoclonals across major Western¹ markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all target populations. The product also includes an in depth review of latest epidemiological trends, lipid lowering treatments/guidelines and latest developments in R&D.

¹ SECONDARY PREVENTION - US, Canada, Australia, UK, France, Italy, Germany, Spain, Other Europe and Australia

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to PCSK9 inhibitors, coronary heart disease (CHD), ischaemic stroke, and peripheral arterial disease (PAD) and other target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

PRODUCT CONTENTS:

Published February 2015 (CAT No: VAMV045)

****This product is composed of two forecast models (.xls) and a summary presentation (.pdf)

Author's note
Contents
Executive Summary
Commercial model: key model outputs
PCSK9 vaccines: predicted venues by scenario to 2030
PCSK9 vaccines: predicted revenues by region to 2030
PCSK9 vaccines: predicted volume to 2030
Patient numbers: PCSK9 vaccines versus anti-PCSK9 mAbs to 2030
Cardiovascular disease (CVD): background and epidemiology
Cardiovascular disease: a major cause of death
The economic burden of cardiovascular disease (US)
The economic burden of cardiovascular disease (EU)
Managing CVD: EU and US lipid guidelines – background
Major changes in new US ATP IV guidelines
Focus on CVD risk groups
CVD risk groups: Heterozygous familial hypercholesterolemia (heFH)
LDL-C treatment goals
LDL-C treatment goals: comparing EU to US
LDL-C treatment goals: ESC/EAS LDL-C treatment targets
LDL-C treatment goals: intervention strategies by risk group/ LDL-C
LDL-C lowering treatments
Statins: lipid lowering intensity levels
Drivers of statin choice
Patient subgroups: statin benefits outweigh risks
Side effects of statins
LDL-C lowering treatment uptake: general
Hospitalized CVD patients discharged on statin therapy, 1996-2006, by EU country
LDL-C lowering treatment uptake: by risk group
LDL-C goal achievement in CVD patients
LDL-C goal achievement in heFH patients
Anti-PCSK9 monoclonal antibodies: Novel LDL-C lowering agents
Background to PCSK9 inhibitors
PCSK9 role in LDL cholesterol (LDL-C) metabolism
PCSK9 inhibition strategies
PCSK9 monoclonal antibodies: current status

Continued.....

Broad target populations for anti-PCSK9 mAbs
PCSK9 monoclonal antibodies: overview of competitor activity
Sanofi Aventis - alirocumab (SAR236553)
Sanofi Aventis - alirocumab: Phase II data
Sanofi Aventis - alirocumab: ODYSSEY program
Sanofi Aventis - alirocumab: Phase III - ODYSSEY results
Submissions of alirocumab (SAR236553) - Praluent[™]
Praluent[™] - market opportunity (US/EU5/Japan)
Amgen - evolocumab (REPATHA[™])
Evolocumab: example Phase III data (TESLA Part B)
Evolocumab: market opportunity (US/EU5/Japan)
Pfizer – bococizumab
Summary of anti-PCSK9 mAbs: outcomes studies
PCSK9 - other targetted therapies
Concerns with anti-PCSK9 monoclonals
Other remaining questions regarding PCSK9 inhibitors
PCSK9 vaccines: background and overview of R&D
PCSK9 vaccine: key model assumptions
The role of a PCSK9 vaccine
PCSK9 vaccine: Target Product Profile (TPP)
PCSK9 vaccine development - AFFiRiS AG
PCSK9 vaccine development – Pfizer
PCSK9 vaccine development – Pfizer (preclinical data)
Pros and cons of PCSK9 vaccine approach
PCSK9 vaccine: modelling commercial potential
Key model inputs: countries & target populations
Key model inputs: vaccine market penetration
Key model inputs: vaccine dosing/pricing
Key model inputs: vaccine discontinuation rate
Key model inputs: summary table
Methodology: definition of risk groups
Modelling methodology
Risk groups modelled
CVD hospital discharges
Death rates CHD
Coronary revascularisation (TCA and CABG combined), hospital discharges
Transluminal coronary angioplasty (TCA) and coronary artery bypass graft (CABG) discharges
Methodology: stroke incidence
Appendix: Anti-PCSK9 monoclonals: List of major clinical trials
ODYSSEY program - overview of Phase III trials
Phase III trials of evolocumab
Phase III trials of bococizumab
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~90 slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model TX vaccine (MS Excel-based)

Title sheet
CHARTS – VALUE
CHARTS – VOLUME
CHARTS – TREATED PATIENTS
Vaccine – Value
Vaccine – Volume
Patients – mAbs
Secondary prevention
Country worksheets →
US
Canada
France
Germany
Italy
Spain
UK
Other Europe
Australia
Source material →
Key inputs
Vaccine price summary
Coronary revascularisation
TCA
CABG
PAD
Stroke
US discharge trends
heFH
LDL-C goals
WHO
Statins in CVD patients
Clinical trials
Total population
Back page

Worksheets ~ 35 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5800.00**[#] (Region license)*
- PRESENTATION OR MODEL ONLY - USD **\$4995** (Region license)*

[#] Indicative rate only. Prevailing rate applied to date of transaction.


*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. UBS Investment Research Morning Espresso – Asia. Available at: view.microbell.com/upfile1/201209/201291184122859.pdf. Accessed: March 2013
2. Sanofi. Crédit Agricole Cheuvreux. Available at: https://www.mercagentes.es/.../SANOFI_MEJORAPO_310712.pdf. Accessed: March 2013
3. JMCP September 2010 - Academy of Managed Care Pharmacy. Available at: www.amcp.org/data/jmcp/September2010.pdf. Accessed: March 2013
4. Appendix E - National Institute for Health and Clinical Excellence. Available at: www.nice.org.uk/nicemedia/live/12048/41706/41706.pdf. Accessed: March 2013
5. Shah ND et al. Long-term medication adherence after myocardial infarction: experience of a community. *Am J Med.* 2009 Oct;122(10):961.e7-13.
6. Colivicchi F et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. *Stroke.* 2007 Oct;38(10):2652-7.
7. WHO Fact sheet No. 310. Available at: <http://www.who.int/mediacentre/factsheets/fs310/en/index.html>. Accessed February 2013
8. Heidenreich PA et al. (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation*, 123(8):933-44.
9. Centers for Disease Control and Prevention (2011) Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors--United States, 2011. *MMWR*, 60 (36): 1248-51.
10. European Association for Cardiovascular Prevention & Rehabilitation. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J.* 2011 Jul;32(14):1769-818.
11. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at: <http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm>. Accessed: March 2013.
12. Bell DA et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. *Ann Clin Biochem.* 2012 Nov;49(Pt 6):534-7.
13. Benn M et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. *J Clin Endocrinol Metab.* 2012 Nov;97(11):3956-64.
14. Health Quality Ontario. Low-density lipoprotein apheresis: an evidence-based analysis. *Ont Health Technol Assess Ser.* 2007;7(5):1-101.
15. O'Kane MJ et al. The detection of heterozygous familial hypercholesterolemia in Ireland. *Adv Ther.* 2012 May;29(5):456-63.
16. Reddy G et al. LDL Lowering After Acute Coronary Syndrome: Is Lower Better? *Curr Treat Options Cardiovasc Med.* 2013 Feb;15(1):33-40.
17. Grundy SM et al. The Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation.* 2004.110(2):227–239.
18. Law MR et al. (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *British Medical Journal*, 326 (7404) :1423-29.
19. Weng TC et al. (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. *Journal of Clinical Pharmacy and Therapeutics*, 35(2):139-51.
20. Adams SP et al. Lipid lowering efficacy of atorvastatin. *Cochrane Database Syst Rev.* 2012 Dec 12;12:CD008226.
21. Kotseva K et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. *Lancet* 2009;373(9667):929-40
22. Melloni C et al. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications Applied and Sustained Over Time (MAINTAIN) registry. *Am Heart J.* 2010 Dec;160(6):1121-9, 1129.e1.
23. Siggaard-Andersen N et al. Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids. *Dan Med J.* 2012 Jul;59(7):A4470
24. Karalis DG et al. Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. *Cholesterol.* 2012;2012:861924.
25. Jones PH et al. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. *J Am Heart Assoc.* 2012 Dec;1(6):e001800.

26. JMelloni C et al. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications Applied aNd SusTAINED Over Time (MAINTAIN) registry. *Am Heart J.* 2010 Dec;160(6):1121-9, 1129.e1.
27. Javed U et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). *Am Heart J.* 2010 Dec;160(6):1130-6, 1136.e1-3.
28. Ferrières J et al. Assessment of lipid-lowering treatment in France--the CEPHEUS study. *Arch Cardiovasc Dis.* 2008 Sep;101(9):557-63.
29. Huijgen R et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. *PLoS One.* 2010 Feb 15;5(2):e9220.
30. IR Conference Call on PCSK9. SAR236553/REGN727 PCSK9 Antibody for Hypercholesterolemia. Phase 3 ODYSSEY Program Underway November 5, 2012. Available at: http://en.sanofi.com/investors/events/corporate/2012/2012-11-05_PCSK9_call.aspx. Accessed: March 2013
31. 31st Annual J. P. Morgan Healthcare Conference. Jan 8, 2013. Available at: <http://investor.regeneron.com/events.cfm>. Accessed: March 2013
32. Galabova G. et al. Affitope®-Based Active Immunization Targeting Pcsk9 For The Treatment Of Atherosclerosis. 80th EAS Congress, Milano, Italy, May 2012
33. European Commission, Eurostat database. Available at: http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database. Accessed: March 2013
34. OECD data. Health Care Utilisation MetaData : Surgical procedures by ICD-9-CM. Available at: <http://stats.oecd.org/index.aspx?queryid=30167#>. Accessed: March 2013
35. National Hospital Discharge Survey. Available at: http://www.cdc.gov/nchs/nhds/nhds_tables.htm. Accessed: March 2013
36. European Cardiovascular Disease Statistics 2012 edition. Available at: www.escardio.org/.../advocacy/EuroHeart/Pages/2012-CVD-statistics.aspx. Accessed: March 2013
37. Bravata DM et al. Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Oct.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009